Midatech Pharma PLC Further re: Notice of General Meeting (6490S)
10 Mars 2023 - 6:52PM
UK Regulatory
TIDMMTPH
RNS Number : 6490S
Midatech Pharma PLC
10 March 2023
10 March 2023
Midatech Pharma PLC
("Midatech" or the "Company")
Further re : Notice of General Meeting - Correction of
Typographical Errors
Further to the announcement made on 8 March 2023 providing
notice of a general meeting (the " GM ") of the Company to be held
on 24 March 2023, and the publication and despatch of a circular to
shareholders containing notice of the resolutions to be considered
at the GM (the " Notice ") and form of proxy (the " Form of Proxy
"), the Company announces the following corrections to certain
typographical errors identified within the Notice and Form of
Proxy:
-- Resolution 4 of the Notice (" Resolution 4 ") refers to a
proposed authority to waive pre-emption rights in respect of the
allotment authority sought by resolution 2 of the Notice which is
limited to an aggregate nominal amount of GBP1,911,169.68.
Accordingly, the waiver of pre-emption rights authority sought by
Resolution 4 should be an amount of GBP1,911,169.68 (not
GBP2,905,400.59 as currently stated in the Notice);
-- Resolution 5 of the Notice (" Resolution 5 ") refers to a
proposed authority to waive pre-emption rights in respect of the
allotment authority sought by resolution 3 of the Notice which is
limited to an aggregate nominal amount of GBP2,300,000.00.
Accordingly, the waiver of pre-emption rights authority sought by
Resolution 5 should be an amount of GBP2,300,000.00 (not
GBP4,200,000 as currently stated in the Notice); and
-- Resolution 4 as described on the Form of Proxy incorrectly
states that it is "To authorise grant the Directors authority to
allot shares in the Company in connection with the grant of the A
Warrants, the B Warrants, the Ladenburg Warrants, the Waiver
Warrants and the Pre-Funded Warrants" (which effectively duplicates
resolution 2 of the Form of Proxy). In accordance with the
resolutions set out in the Notice, resolution 4 of the Form of
Proxy should instead state that it is "To disapply statutory
pre-emption rights in connection with the grant of the A Warrants,
the B Warrants, the Ladenburg Warrants, the Waiver Warrants and the
Pre-Funded Warrants".
As such errors are administrative in nature, no new Notice will
be published and the aforementioned amendments to Resolution 4 and
Resolution 5 will be effected by a motion to be passed at the GM.
Furthermore, no new Form of Proxy will be posted to shareholders
but a copy of the corrected Form of Proxy will be made available on
the Company's website at: www.midatechpharma.com/. Any shareholder
who wishes to change any proxy instructions already submitted may
do so by submitting a new proxy appointment using the method set
out in the notes to the Notice.
For more information, please contact : Midatech Pharma PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)29 2048 0180
www.midatechpharma.com
Strand Hanson Limited (Nominated Adviser and Broker)
James Dance / Matthew Chandler / Rob Patrick
Tel: +44 (0)20 7409 3494
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Edison Group (US Investor Relations)
Alyssa Factor
Tel: +1 (860) 573 9637
Email: afactor@edisongroup.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FURBRGDXGUBDGXG
(END) Dow Jones Newswires
March 10, 2023 12:52 ET (17:52 GMT)
Midatech Pharma (LSE:MTPH)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Midatech Pharma (LSE:MTPH)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024